药师帮“向上走”：深耕供应链，驱动韧性增长

Core Viewpoint - The article discusses the strategic shift of Yaoshi Bang, a leading digital comprehensive service platform in the outpatient pharmaceutical industry, which has proposed the "Upward Move" strategy to enhance product offerings, deepen brand partnerships, and develop proprietary brands, aiming for resilient growth amidst a challenging market environment [2][7][15]. Group 1: Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [2]. - The net profit attributable to shareholders is expected to be 140.4 billion yuan, reflecting a significant decline of nearly 12%, indicating the first negative growth in five years [2]. - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm, leading to increased demands for supply chain integration capabilities [2][10]. Group 2: Company Performance - Yaoshi Bang achieved a revenue of 17.904 billion yuan in 2024, representing a year-on-year growth of 5.5%, with net profit turning positive for the first time at 30.01 million yuan, and adjusted net profit reaching 1.57 billion yuan, up 20.1% [8][11]. - The operating cash flow remained positive at 656 million yuan, showing a 45% year-on-year increase, indicating robust growth across economic cycles [8]. Group 3: Strategic Initiatives - The "Upward Move" strategy focuses on three dimensions: enriching product offerings, deepening brand collaborations, and building proprietary brands, which collectively enhance supply chain capabilities and operational service levels [2][9][15]. - Yaoshi Bang has established a comprehensive marketing system, covering 491,000 pharmacies and 330,000 grassroots medical institutions, achieving a monthly active buyer count of 433,000, showcasing strong market penetration [10][11]. - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs, with a transaction scale of 651 million yuan, reflecting a 152% year-on-year growth [11][13]. Group 4: Market Trends - The total number of pharmacies in China reached 700,881 by Q4 2024, with a year-on-year growth of 2.3%, but a quarter-on-quarter decline of 0.5%, indicating a trend of increasing store closures [4]. - The retail terminal pharmaceutical sales scale is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, while sales of health products and medical devices have seen significant declines of 24.8% and 20%, respectively [5][10].